- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03660917
Riluzole in Patients With Spinocerebellar Ataxia Type 7
Riluzole in Patients With Spinocerebellar Ataxia Type 7: a Randomized , Double-blind, Placebo-controlled Pilot Trial With a Lead in Phase
Study Overview
Detailed Description
The investigators propose a clinical trial in SCA7 patients performing a serial evaluation of riluzole effects on stringent outcome measures: ophthalmological metrics, scale for the assessment and rating of ataxia (SARA) scores, and safety biomarkers.
The study design will be a randomized , double-blind, placebo-controlled pilot trial with a lead-in phase. The design will include a run-in phase of 6 months for all the participants, assessing ophthalmological metrics and SARA scores at the month 0, 3, and 6. Then one arm will undergo riluzole for other 12 months, while the other will take placebo for 6 months, and riluzole for the following 6 months; from both groups the same evaluations will be obtained at the month 12, 15 and 18 of the study.
Thirty-four patients will be enrolled at 4 clinical Centers (3 in Italy and one in U.S.). The clinical epidemiology aspects (design of the study, statistical analysis and enrollment process) will be followed by National Rare Diseases Centre and Complex Diseases Group of National Centre of Epidemiology, Surveillance and Health Promotion of National Institute of Health.
Eligible subjects for this study are patients (at least 7-year old) with positive genetic test for SCA7. Serious systemic illnesses or conditions (cardiac, haematologic and hepatic diseases) known for enhancing the side effects of riluzole, pregnancy or breastfeeding will be exclusion criteria.
Participants will be randomly assigned (1:1) to riluzole (50 mg twice daily) or placebo. In pre-pubertal subjects the dosage will be adjusted on a mg/m2 basis according to the recommended human daily dose (100 mg).
At baseline and after 3, 6, 12, 15 and 18 months, symptoms, physical and neurological signs, and SARA score will be recorded. At the same time points the following quantitative ophthalmologic assessments will be performed:
- corrected visual acuity (right eye and left eye measurements) expressed as logMAR units with the ETDRS chart (either back-illuminated or projected).
- Color vision via a Farnsworth D15 Arrangement Test.
- Visual evoked potential are elicited using transient Pattern Reversal stimuli and monocular stimulation.
- Electroretinography
- Optical Coherence tomography with macular map of both eyes.
- Computerized visual field examination by standard automated perimetry and kinetic perimetry Every three months electrocardiogram and a laboratory profile will be obtained for drug safety.
The co-primary endpoints will be the proportion of patients with stability of SARA score and visual acuity (in log MAR units) at 18 months, compared to the mean values of t0-t3-t6 evaluations.
A sample size of 17 patients per group (a total of 34 patients) had 80% power and an α value of 10% to detect a difference between the two groups of 35% in the co-primary end points. This calculation took into account published data on riluzole in CA.
Data will be expressed as mean (SD) for continuous variables and as proportions for categorical variables. Comparisons between riluzole and placebo group will be assessed using the t test for unpaired data for continuous variables and odds ratio with a relative 95% CI for categorical data. An intention-to-treat analysis will be done adopting a last observation carried forward method. A logistic regression model will be done at 18 months to adjust the results for the main baseline characteristics; p values less than 0.05 will be considered significant.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Rome, Italy, 00139
- Center for Experimental Neurological Therapies (CENTERS), S. Andrea Hospital, Faculty of Medicine and Psychology, "Sapienza" University of Rome
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- positive genetic test for SCA7.
Exclusion Criteria:
- cardiac arrhythmias;
- haematologic diseases;
- hepatic diseases with serum values of alanine aminotransferase, aspartate aminotransferase or bilirubin > 1·5 times above normal limit;
- pregnancy (women of childbearing potential agreed to use contraception);
- breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Riluzole
Riluzole 50 mg twice daily for 12 months in the treated group.
In pre-pubertal subjects the dosage will be adjusted on a mg/m2 basis according to the recommended human daily dose (RHDD; 100 mg).
|
Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months in the treated group.
|
Placebo Comparator: Placebo + riluzole
Placebo twice daily for 6 months and riluzole 50 mg twice daily for the following 6 months in the comparison group
|
Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months in the treated group.
Placebo drug for 6 months, however they will receive riluzole during the last 6 months of study, so that all patients will undergo the active drug in the last phase of the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
visual acuity expressed as log MAR units
Time Frame: 18 months
|
the metric to quantify the best corrected visual acuity, by applying the ETDRS chart (either back-illuminated or projected) with the patient's correction for distance
|
18 months
|
the proportion of patients with stable Scale for the assessment and rating of ataxia (SARA) score
Time Frame: 18 months
|
neurological assessment for ataxia. It has eight categories with accumulative score ranging from 0 (no ataxia) to 40 (most severe ataxia). When completing the outcome measure each category is assessed and scored accordingly. Scores for the eight items range as follows: Gait (0-8 points), Stance (0-6 points), Sitting (0-4 points) Speech disturbance (0-6 points) Finger chase (0-4 points) Nose-finger test (0-4 points) Fast alternating hand movement (0-4 points) Heel-shin slide (0-4 points) Once each of the 8 categories have been assessed, the total is calculated to determine the severity of ataxia. For motor activities of the four extremities (items 5-8), assessments are performed bilaterally, and the mean values are used to obtain the total score. |
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Farnsworth D15 Arrangement Test
Time Frame: 18 months
|
quantitative ophthalmologic assessments
|
18 months
|
Visual evoked potentials
Time Frame: 18 months
|
quantitative ophthalmologic assessments
|
18 months
|
Electroretinography
Time Frame: 18 months
|
quantitative ophthalmologic assessments
|
18 months
|
Optical Coherence tomography
Time Frame: 18 months
|
quantitative ophthalmologic assessments
|
18 months
|
Scale for the assessment and rating of ataxia (SARA) score
Time Frame: 18 months
|
neurological assessment for ataxia. It has eight categories with accumulative score ranging from 0 (no ataxia) to 40 (most severe ataxia). When completing the outcome measure each category is assessed and scored accordingly. Scores for the eight items range as follows: Gait (0-8 points), Stance (0-6 points), Sitting (0-4 points) Speech disturbance (0-6 points) Finger chase (0-4 points) Nose-finger test (0-4 points) Fast alternating hand movement (0-4 points) Heel-shin slide (0-4 points) Once each of the 8 categories have been assessed, the total is calculated to determine the severity of ataxia. For motor activities of the four extremities (items 5-8), assessments are performed bilaterally, and the mean values are used to obtain the total score. |
18 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Genetic Diseases, Inborn
- Neurodegenerative Diseases
- Dyskinesias
- Spinal Cord Diseases
- Heredodegenerative Disorders, Nervous System
- Cerebellar Diseases
- Ataxia
- Cerebellar Ataxia
- Spinocerebellar Ataxias
- Spinocerebellar Degenerations
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Neuroprotective Agents
- Protective Agents
- Anticonvulsants
- Riluzole
Other Study ID Numbers
- AIFA-2016-02365063
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Riluzole
-
Aquestive TherapeuticsCovance; inVentiv Health ClinicalTerminatedAmyotrophic Lateral SclerosisUnited States
-
Uniformed Services University of the Health SciencesU.S. Army Medical Research and Development CommandCompleted
-
Peking University Third HospitalThe Second Hospital of Hebei Medical UniversityRecruitingAmyotrophic Lateral SclerosisChina
-
University of UtahOhio State UniversityRecruitingAtrial Fibrillation ParoxysmalUnited States
-
Aquestive TherapeuticsCovance; Inventiv HealthWithdrawn
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedUnspecified Adult Solid Tumor, Protocol Specific | Metastatic CancerUnited States
-
AOSpine North America Research NetworkCompletedCervical Spondylotic MyelopathyUnited States, Canada
-
S. Andrea HospitalAgenzia Italiana del FarmacoCompleted
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)CompletedMelanoma (Skin)United States
-
Yale UniversityNational Institute of Mental Health (NIMH)CompletedObsessive-compulsive Disorder | OcdUnited States